Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00398138CT.gov Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | — | Completed | — | — | — |
NCT00002475CT.gov Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sargramostim (this asset) | Memorial Sloan Kettering Cancer Center | P2 | BB · 64 |
| Cis-Diamminedichloroplatinum Ii | Dr Jean Yannis PERENTES | P2 | BB |
| Adriamycin | Mayo Clinic | P2 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | BB |
| Tamoxifen | Ottawa Regional Cancer Centre | P2 | B |
| L-Alanosine | Memorial Sloan Kettering Cancer Center | P2 | B |
| Alpha-Interferon | St. Vincent Medical Center - Los Angeles | P2 | B |
| 18f-fspg | Andrei Iagaru | P2 | B |
| Fludeoxyglucose | Andrei Iagaru | P2 | B |
+42 more in the Malignant Mesothelioma cohort
Other indications for Sargramostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Chronic Myeloid Leukemia | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sargramostim in Malignant Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sargramostim-malignant-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →